| 產(chǎn)品編號(hào) | bs-1083R |
| 英文名稱 | VEGFR3 Rabbit pAb |
| 中文名稱 | 血管內(nèi)皮細(xì)胞生長(zhǎng)因子受體3抗體 |
| 別 名 | Vascular endothelial growth factor receptor 3; Tyrosine-protein kinase; AI323512; Chy; FLT41; LMPH1A; LOC285682; PCL; VEGFR-3; fms-related tyrosine kinase 4; VGFR3_MOUSE. |
 |
Specific References (2) | bs-1083R has been referenced in 2 publications.
[IF=2.679] Michiko Jo. et al. Impact of Goreisan components on rat mesenteric collecting lymphatic vessel pumping. MICROCIRCULATION. 2022 Oct;:e12788 WB ; Rat.
[IF=1.68] Sun, Y., et al. "A Reproducible In-vivo Model of Lymphatic Malformation in Rats." Journal of comparative pathology 145.4 (2011): 390-398. IHC-P ; Rat.
|
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 發(fā)育生物學(xué) 信號(hào)轉(zhuǎn)導(dǎo) 細(xì)胞凋亡 激酶和磷酸酶 細(xì)胞膜受體 血管內(nèi)皮細(xì)胞 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human,Mouse,Rat (predicted: Rabbit,Pig,Dog,Horse) |
| 產(chǎn)品應(yīng)用 | IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 151 kDa |
| 檢測(cè)分子量 | |
| 細(xì)胞定位 | 細(xì)胞核 細(xì)胞漿 細(xì)胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from mouse VEGFR-3: 901-1000/1263 <Cytoplasmic> |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
Vascular endothelial growth factors (VEGFs) are a family of closely related growth factors having a conserved pattern of eight cysteine esidues and sharing common VEGF receptors. VEGFs stimulate the proliferation of endothelial cells, induce angiogenesis, and increase vascular permeability in both large and small vessels. The mitogenic activity of VEGFs appears to be mediated by specific VEGF receptors. VEGF Receptor 3 is one of the five receptor tyrosine kinases (RTKs) (VEGF Receptor 1/Flt1, VEGF Receptor 2/KDR/Flk1, VEGF Receptor 3/Flt4, tie1 and tek/tie2) whose expression is almost exclusively restricted to endothelial cells. Function: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced production of VEGFC, and to a lesser degree VEGFA, thereby creating a positive feedback loop that enhances FLT4 signaling. Modulates KDR signaling by forming heterodimers. Mediates activation of the MAPK1/ERK2, MAPK3/ERK1 signaling pathway, of MAPK8 and the JUN signaling pathway, and of the AKT1 signaling pathway. Phosphorylates SHC1. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Promotes phosphorylation of MAPK8 at 'Thr-183' and 'Tyr-185', and of AKT1 at 'Ser-473'. Subunit: Interacts with VEGFC and VEGFD. Monomer in the absence of bound VEGFC or VEGFD. Homodimer in the presence of bound VEGFC or VEGFD. Can also form a heterodimer with KDR. Interacts with PTPN14; the interaction is enhanced by stimulation with VEGFC. Interacts with CRK, GRB2, PTK2/FAK1, SHC1, PIK3R1 and PTPN11/SHP-2. Identified in a complex with SRC and ITGB1. Subcellular Location: Cell membrane; Single-pass type I membrane protein. Cytoplasm. Nucleus. Note=Ligand-mediated autophosphorylation leads to rapid internalization. Tissue Specificity: Expressed in adult lung and liver, and in fetal liver, brain, intestine and placenta. Post-translational modifications: Autophosphorylated on tyrosine residues upon ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Phosphorylation in response to H(2)O(2) is mediated by a process that requires SRC and PRKCD activity. Phosphorylation at Tyr-1068 is required for autophosphorylation at additional tyrosine residues. Phosphorylation at Tyr-1063 and Tyr-1337 is important for interaction with CRK and subsequent activation of MAPK8. Phosphorylation at Tyr-1230, Tyr-1231 and Tyr-1337 is important for interaction with GRB2 and subsequent activation of the AKT1 and MAPK1/ERK2 and/or MAPK3/ERK1 signaling pathways. In response to endothelial cell adhesion onto collagen, can also be phosphorylated in the absence of FLT4 kinase activity by SRC. Similarity: Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily. Contains 7 Ig-like C2-type (immunoglobulin-like) domains. Contains 1 protein kinase domain. SWISS: P35917 Gene ID: 14257 Database links: Entrez Gene: 2324 Human Entrez Gene: 14257 Mouse Omim: 136352 Human SwissProt: P35916 Human SwissProt: P35917 Mouse Unigene: 646917 Human Unigene: 3291 Mouse Unigene: 81043 Rat VEGFR3又稱FLt4主要在成熟組織的淋巴管內(nèi)皮細(xì)胞上表達(dá),VEGF-R3與淋巴管內(nèi)皮細(xì)胞增殖和遷移有關(guān)，有刺激淋巴管新生的作用，目前多用于腫瘤轉(zhuǎn)移方面的研究。 |
| 產(chǎn)品圖片 |
Paraformaldehyde-fixed, paraffin embedded Human Breast Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with VEGFR3 Polyclonal Antibody, Unconjugated (bs-1083R) at 1:200 overnight at 4°C, followed by co
Paraformaldehyde-fixed, paraffin embedded Rat Placenta; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with VEGFR3 Polyclonal Antibody, Unconjugated (bs-1083R) at 1:200 overnight at 4°C, followed by conjugati
Paraformaldehyde-fixed, paraffin embedded Mouse Kidney; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with VEGFR3 Polyclonal Antibody, Unconjugated (bs-1083R) at 1:200 overnight at 4°C, followed by conjugati
Paraformaldehyde-fixed, paraffin embedded Rat Kidney; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with VEGFR3 Polyclonal Antibody, Unconjugated (bs-1083R) at 1:200 overnight at 4°C, followed by conjugation
|
